-去背.png){kind=logo}
2025.6.11
AAVnerGene and TFBS Bioscience Announce Collaboration to Develop Innovative AAV Vector Technology Platform for Gene Therapy
Rockville, Maryland, and Taipei, Taiwan – 16th July 2025 — AAVnerGene Inc. and TFBS Bioscience Inc. today announced a collaboration on the development and application of innovative adeno-associated virus (AAV) vector technologies for manufacturing, including key areas such as AAV tropism enhancement and manufacturing process optimization.
AAVnerGene focuses on developing novel AAV technologies, including improvement of AAV tropism and production efficiency. Its AAVone single-plasmid system enables higher efficiency and purity while simplifying production procedures. TFBS Bioscience specializes in one-stop-shop viral vector manufacturing services, from R&D and process development to GMP manufacturing and quality testing.
Under this collaboration, both parties will combine early-stage platform research and GMP manufacturing expertise to optimize AAV vector production technologies, enhance scalability, and reduce manufacturing costs.
“Through this collaboration, AAVnerGene will leverage TFBS Bioscience’s GMP manufacturing capabilities to strengthen its presence in the East Asian market,” said Daozhan Yu, President and CEO of AAVnerGene.
“We believe this collaboration will drive the development of innovative AAV vector technologies to deliver safer and more effective gene therapies worldwide,” said Dr. Tatung Yuan, Chairman and CEO of TFBS Bioscience.
This collaboration highlights both parties’ commitment to advancing AAV vector applications for gene therapy across the Asia-Pacific and North American markets.
About AAVnerGene
AAVnerGene Inc., headquartered in Rockville, Maryland, USA, is dedicated to advancing gene therapy through AAV platform technologies.
About TFBS Bioscience Inc.
TFBS Bioscience Inc. (TFBS) provides integrated viral vector CDMO and CRO services for gene and cell therapy development. Website: www.tfbsbio.com